Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals

results of a Delphi consensus

V. Di Marco, A. Alberti, G. Angarano, M. Colombo, G. Di Perri, G. B. Gaeta, G. Ippolito, A. Mangia, P. Pasqualetti, A. Craxì

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To optimize the management of patients with chronic hepatitis C virus (HCV). MATERIALS AND METHODS: We developed two questionnaires to determine Italian healthcare professionals' opinions on the overall management of HCV chronic liver disease and the use of direct-acting antivirals (DAAs) in the treatment of HCV. A Delphi consensus method using the RAND/UCLA appropriateness method was used to determine opinions of an expert panel (EP) of specialists. RESULTS: Overall 443 physicians from 167 Italian centres completed the two questionnaires. The EP confirmed the importance of collaboration with general practitioners (GPs) and HCV testing in high-risk groups, but did not agree on treating patients over 80 years of age with DAAs. Over 90% agreed that it was important to quantify HCV-RNA, determine genotype, and test for anti-HIV and HBsAg before starting DAAs. Transient elastography (FibroScan®) was used by >90% to evaluate the stage of liver fibrosis while serum biomarkers were used by <20%. Adherence to therapy, drug-drug interactions and the possibility of treating advanced liver disease were decisive factors in therapy choice. Monthly monitoring during therapy was considered appropriate and 80% were in favor of HCV-RNA testing 24 weeks after the end of the therapy to confirm sustained virological response (SVR). Over 80% agreed that it was necessary to continue follow-up of patients with advanced fibrosis/cirrhosis. CONCLUSIONS: Scientific organizations should review their guideline recommendations to facilitate access to DAAs.

Original languageEnglish
Pages (from-to)7024-7033
Number of pages10
JournalEuropean Review for Medical and Pharmacological Sciences
Volume22
Issue number20
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Hepacivirus
Hepatitis
Antiviral Agents
Liver Diseases
Fibrosis
RNA
Elasticity Imaging Techniques
Expert Testimony
Chronic Hepatitis
Therapeutics
Hepatitis B Surface Antigens
Drug Interactions
Liver Cirrhosis
General Practitioners
Chronic Disease
Biomarkers
Genotype
HIV
Organizations
Guidelines

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals : results of a Delphi consensus. / Di Marco, V.; Alberti, A.; Angarano, G.; Colombo, M.; Di Perri, G.; Gaeta, G. B.; Ippolito, G.; Mangia, A.; Pasqualetti, P.; Craxì, A.

In: European Review for Medical and Pharmacological Sciences, Vol. 22, No. 20, 01.10.2018, p. 7024-7033.

Research output: Contribution to journalArticle

@article{5fbb07f5446c42b18c956396f834a7cf,
title = "Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus",
abstract = "OBJECTIVE: To optimize the management of patients with chronic hepatitis C virus (HCV). MATERIALS AND METHODS: We developed two questionnaires to determine Italian healthcare professionals' opinions on the overall management of HCV chronic liver disease and the use of direct-acting antivirals (DAAs) in the treatment of HCV. A Delphi consensus method using the RAND/UCLA appropriateness method was used to determine opinions of an expert panel (EP) of specialists. RESULTS: Overall 443 physicians from 167 Italian centres completed the two questionnaires. The EP confirmed the importance of collaboration with general practitioners (GPs) and HCV testing in high-risk groups, but did not agree on treating patients over 80 years of age with DAAs. Over 90{\%} agreed that it was important to quantify HCV-RNA, determine genotype, and test for anti-HIV and HBsAg before starting DAAs. Transient elastography (FibroScan{\circledR}) was used by >90{\%} to evaluate the stage of liver fibrosis while serum biomarkers were used by <20{\%}. Adherence to therapy, drug-drug interactions and the possibility of treating advanced liver disease were decisive factors in therapy choice. Monthly monitoring during therapy was considered appropriate and 80{\%} were in favor of HCV-RNA testing 24 weeks after the end of the therapy to confirm sustained virological response (SVR). Over 80{\%} agreed that it was necessary to continue follow-up of patients with advanced fibrosis/cirrhosis. CONCLUSIONS: Scientific organizations should review their guideline recommendations to facilitate access to DAAs.",
author = "{Di Marco}, V. and A. Alberti and G. Angarano and M. Colombo and {Di Perri}, G. and Gaeta, {G. B.} and G. Ippolito and A. Mangia and P. Pasqualetti and A. Crax{\`i}",
year = "2018",
month = "10",
day = "1",
doi = "10.26355/eurrev_201810_16174",
language = "English",
volume = "22",
pages = "7024--7033",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "20",

}

TY - JOUR

T1 - Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals

T2 - results of a Delphi consensus

AU - Di Marco, V.

AU - Alberti, A.

AU - Angarano, G.

AU - Colombo, M.

AU - Di Perri, G.

AU - Gaeta, G. B.

AU - Ippolito, G.

AU - Mangia, A.

AU - Pasqualetti, P.

AU - Craxì, A.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - OBJECTIVE: To optimize the management of patients with chronic hepatitis C virus (HCV). MATERIALS AND METHODS: We developed two questionnaires to determine Italian healthcare professionals' opinions on the overall management of HCV chronic liver disease and the use of direct-acting antivirals (DAAs) in the treatment of HCV. A Delphi consensus method using the RAND/UCLA appropriateness method was used to determine opinions of an expert panel (EP) of specialists. RESULTS: Overall 443 physicians from 167 Italian centres completed the two questionnaires. The EP confirmed the importance of collaboration with general practitioners (GPs) and HCV testing in high-risk groups, but did not agree on treating patients over 80 years of age with DAAs. Over 90% agreed that it was important to quantify HCV-RNA, determine genotype, and test for anti-HIV and HBsAg before starting DAAs. Transient elastography (FibroScan®) was used by >90% to evaluate the stage of liver fibrosis while serum biomarkers were used by <20%. Adherence to therapy, drug-drug interactions and the possibility of treating advanced liver disease were decisive factors in therapy choice. Monthly monitoring during therapy was considered appropriate and 80% were in favor of HCV-RNA testing 24 weeks after the end of the therapy to confirm sustained virological response (SVR). Over 80% agreed that it was necessary to continue follow-up of patients with advanced fibrosis/cirrhosis. CONCLUSIONS: Scientific organizations should review their guideline recommendations to facilitate access to DAAs.

AB - OBJECTIVE: To optimize the management of patients with chronic hepatitis C virus (HCV). MATERIALS AND METHODS: We developed two questionnaires to determine Italian healthcare professionals' opinions on the overall management of HCV chronic liver disease and the use of direct-acting antivirals (DAAs) in the treatment of HCV. A Delphi consensus method using the RAND/UCLA appropriateness method was used to determine opinions of an expert panel (EP) of specialists. RESULTS: Overall 443 physicians from 167 Italian centres completed the two questionnaires. The EP confirmed the importance of collaboration with general practitioners (GPs) and HCV testing in high-risk groups, but did not agree on treating patients over 80 years of age with DAAs. Over 90% agreed that it was important to quantify HCV-RNA, determine genotype, and test for anti-HIV and HBsAg before starting DAAs. Transient elastography (FibroScan®) was used by >90% to evaluate the stage of liver fibrosis while serum biomarkers were used by <20%. Adherence to therapy, drug-drug interactions and the possibility of treating advanced liver disease were decisive factors in therapy choice. Monthly monitoring during therapy was considered appropriate and 80% were in favor of HCV-RNA testing 24 weeks after the end of the therapy to confirm sustained virological response (SVR). Over 80% agreed that it was necessary to continue follow-up of patients with advanced fibrosis/cirrhosis. CONCLUSIONS: Scientific organizations should review their guideline recommendations to facilitate access to DAAs.

UR - http://www.scopus.com/inward/record.url?scp=85056251540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056251540&partnerID=8YFLogxK

U2 - 10.26355/eurrev_201810_16174

DO - 10.26355/eurrev_201810_16174

M3 - Article

VL - 22

SP - 7024

EP - 7033

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 20

ER -